These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1716 related articles for article (PubMed ID: 33734065)

  • 1. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates.
    Behr MA; Divangahi M; Schurr E
    J Infect Dis; 2021 Feb; 223(2):189-191. PubMed ID: 33535239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.
    Jin P; Li J; Pan H; Wu Y; Zhu F
    Signal Transduct Target Ther; 2021 Feb; 6(1):48. PubMed ID: 33531462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.
    Peter J
    S Afr Med J; 2021 Feb; 111(4):291-294. PubMed ID: 33944757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine safety - is the SARS-CoV-2 vaccine any different?
    Tau N; Yahav D; Shepshelovich D
    Hum Vaccin Immunother; 2021 May; 17(5):1322-1325. PubMed ID: 33270474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An
    Dar HA; Waheed Y; Najmi MH; Ismail S; Hetta HF; Ali A; Muhammad K
    J Immunol Res; 2020; 2020():8893483. PubMed ID: 33274246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
    Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
    Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.
    Anand U; Jakhmola S; Indari O; Jha HC; Chen ZS; Tripathi V; Pérez de la Lastra JM
    Front Immunol; 2021; 12():658519. PubMed ID: 34276652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A promising inactivated whole-virion SARS-CoV-2 vaccine.
    Isakova-Sivak I; Rudenko L
    Lancet Infect Dis; 2021 Jan; 21(1):2-3. PubMed ID: 33069282
    [No Abstract]   [Full Text] [Related]  

  • 16. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
    Pascolo S
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33572452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of approved COVID-19 vaccines.
    Jamkhande A; Khairnar MR; Gavali N; Patil Y; Kapare SS; Bhosale KP
    Rocz Panstw Zakl Hig; 2021; 72(3):245-252. PubMed ID: 34553878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2020 race towards SARS-CoV-2 specific vaccines.
    Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D
    Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer.
    Chen Y; Cheng L; Lian R; Song Z; Tian J
    Biosci Trends; 2021 May; 15(2):64-73. PubMed ID: 33746182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.